Prothena Corporation plc: Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update
VITAL study 9-month results expected to be presented at a medical conference in 2021
Prasinezumab
Results from Part 2 of the PASADENA study expected to be presented at an upcoming medical conference
PRX004
PRX005
IND expected by 3Q 2021
$80 million potential payment from Bristol Myers Squibb upon exercising their US license option in 2021
PRX012, a potential treatment for Alzheimer s disease, is a high affinity monoclonal antibody targeting a key epitope within the N-terminus of Aß
IND expected by 1Q 2022
Upcoming Investor Conferences
Members of the senior management team will present and participate in investor meetings at the following upcoming investor conferences:
Published: May 10, 2021
NEW YORK, May 10, 2021 (GLOBE NEWSWIRE)
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2021.
“We continued to make significant strides in the quarter toward becoming a premier biopharmaceutical company focused on delivering potentially life-changing medicines to people living with serious CNS conditions. We successfully filed our NDA for AXS-05 for the treatment of MDD with the FDA, which was granted Priority Review, and are on track to file our NDA for AXS-07 for the acute treatment of migraine this quarter,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “Pre-commercial activities are intensifying as planned to ensure launch readiness assuming FDA approval. The rest of our pipeline continues to progress with the anticipated initiation of the plann
AXS-07 for migraine, NDA submission (2Q 2021)
AXS-05 for smoking cessation, FDA meeting (3Q 2021)
AXS-05 for MDD, commercial launch, if approved (2H 2021)
Clinical Trial Readouts:
Clinical Trial Initiations:
Upcoming Scientific Conferences
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting, May 17-20, 2021
American Society for Clinical Psychopharmacology (ASCP) annual meeting, June 1-4, 2021
American Headache Society (AHS) annual meeting, June 3-6, 2021
Upcoming Investor Conferences
BofA Health Care Conference, May 11, 2021 (to be webcast)
RBC Capital Markets Global Healthcare Conference, May 18, 2021 (to be webcast)
UBS Global Healthcare Virtual Conference, May 24, 2021 (to be webcast)
William Blair Growth Stock Conference, June 3, 2021 (to be webcast)
First Quarter 2021 Financial Results
uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Provention Bio Reports First Quarter 2021 Financial Results and Provides Business Update
News provided by
Share this article
Share this article
RED BANK, N.J., May 6, 2021 /PRNewswire/ Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results and provided a business update for the first quarter ended March 31, 2021. The first quarter of 2021 marked another quarter of strong execution across Provention Bio as we continue to advance our portfolio of autoimmunology therapeutic candidates focused on intercepting and preventing life-threatening and life-impacting diseases, stated Ashleigh Palmer, CEO of Provention Bio. Mr. Palmer continued, Our near-term focus is appropriately concentrated on the BLA filing for teplizumab and the upcoming FDA Advisory Committee meeting on May 27. We believe this Advisory Committee meeting s agenda will include examination of type 1 diabet